Volume 17, Issue 1 (March-2025 2025)                   Iranian Journal of Blood and Cancer 2025, 17(1): 29-39 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Taghizadeh A, Salek R. Evaluation of Complications and Treatment Outcomes Following Intraluminal Brachytherapy after Definitive Chemoradiation in Patients with Esophageal Cancer. Iranian Journal of Blood and Cancer 2025; 17 (1) :29-39
URL: http://ijbc.ir/article-1-1698-en.html
Evaluation of Complications and Treatment Outcomes Following Intraluminal Brachytherapy after Definitive Chemoradiation in Patients with Esophageal Cancer
Azadeh Taghizadeh *1 , Roham Salek1
1- Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:   (610 Views)

Background: Limited data exist on complications and treatment outcomes following brachytherapy after chemoradiation in esophageal cancer. This study aimed to assess complications and treatment outcomes after intraluminal brachytherapy post-definitive chemoradiation.
Methods and Materials: This retrospective cohort study included esophageal cancer patients treated at Imam Reza Radiotherapy Center, Mashhad, Iran (2016-2023). Patients received chemoradiotherapy with paclitaxel-carboplatin, cisplatin-irinotecan, or cisplatin-5-FU (5-6 weeks), with a total radiation dose of ≥45 Gray. After a two-week rest, they underwent HDR brachytherapy with cobalt-60 and were followed monthly for one year.
Results: A total of 125 patients (mean age: 71.08±10.67 years) were evaluated. The overall survival (OS) and disease-free interval (DFI) were 47.26 and 22.62 months, respectively. The most common tumor location was the middle esophagus, and the most common grade was G2. An ECOG score <2 was observed in 96 patients. No significant association was found between OS and DFI with tumor location, grade, dysphagia level, or functional index. However, brachytherapy dose, radiotherapy dose, and chemotherapy regimen were significantly associated with OS, but not with DFI. Post-treatment complications occurred in 98 patients, including local recurrence in 39 cases. Patients without complications had a mean DFI and OS of 54 and 55 months, respectively, while those with complications had 37 and 50 months. Complications were significantly associated with DFI but not with OS. Complete response was seen in 106 patients, significantly correlating with OS (P=0.003) and DFI (P<0.001). Patients with local and distant recurrence had an 11-fold higher mortality risk.
Conclusion: Intraluminal brachytherapy after definitive chemoradiation plays a crucial role in treatment management for esophageal cancer. It should be considered as a treatment option, but further studies with larger sample sizes are needed for routine implementation.

Keywords: Brachytherapy, Esophageal Cancer, Definitive Chemoradiation, Overall survival
Full-Text [PDF 527 kb]   (231 Downloads)    
: Original Article | Subject: Gastroentrology
Received: 2025/02/2 | Accepted: 2025/03/5 | Published: 2025/03/30
References
1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. The Lancet. 2013;381(9864):400-12. [DOI:10.1016/S0140-6736(12)60643-6]
2. Safaei AM, Ghalehtaki R, Khanjani N, Farazmand B, Babaei M, Esmati E. High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results. Journal of Contemporary Brachytherapy. 2017;9(1):30-5. [DOI:10.5114/jcb.2017.65147]
3. Jayaprakash S, Hegde M, Girisa S, Alqahtani MS, Abbas M, Lee EH, Yap KC, Sethi G, Kumar AP, Kunnumakkara AB. Demystifying the functional role of nuclear receptors in esophageal cancer. International Journal of Molecular Sciences. 2022 Sep 19;23(18):10952. [DOI:10.3390/ijms231810952]
4. https://www.cancerresearchuk.org/about-cancer/oesophageal-cancer/survival
5. Bhatt L, Tirmazy S, Sothi S. Intraluminal High Dose Rate Brachytherapy for Palliation of Dysphagia in Cancer of the Oesophagus. Clinical Oncology. 2011;23(3):S30. [DOI:10.1016/j.clon.2011.01.399]
6. Sjödahl K, Lu Y, Nilsen TI, Ye W, Hveem K, Vatten L, et al. Smoking and alcohol drinking in relation to risk of gastric cancer: a population‐based, prospective cohort study. International journal of cancer. 2007;120(1):128-32. [DOI:10.1002/ijc.22157]
7. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Annals of internal medicine. 1999;130(11):883-90. [DOI:10.7326/0003-4819-130-11-199906010-00003]
8. Ding G-C, Ren J-L, Chang F-B, Li J-L, Yuan L, Song X, et al. Human papillomavirus DNA and P16INK4A expression in concurrent esophageal and gastric cardia cancers. World journal of gastroenterology: WJG. 2010;16(46):5901. [DOI:10.3748/wjg.v16.i46.5901]
9. Kamath A, Wu T-T, Heitmiller R, Daniel R, Shah K. Investigation of the association of esophageal carcinoma with human papillomaviruses. Diseases of the Esophagus. 2000;13(2):122-4. [DOI:10.1046/j.1442-2050.2000.00098.x]
10. Ponvilawan B, Rittiphairoj T, Charoenngam N, Rujirachun P, Wattanachayakul P, Tornsatitkul S, et al. Association between Chronic Hepatitis C Virus Infection and Esophageal Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology. 2022;56(1):55-63. [DOI:10.1097/MCG.0000000000001532]
11. Chen T, Cheng H, Chen X, Yuan Z, Yang X, Zhuang M, et al. Family history of esophageal cancer increases the risk of esophageal squamous cell carcinoma. Scientific reports. 2015;5(1):1-9. [DOI:10.1038/srep16038]
12. Sharma P, Jain S, Karunanithi S, Pal S, Julka PK, Thulkar S, et al. Diagnostic accuracy of 18 F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma. European journal of nuclear medicine and molecular imaging. 2014;41:1084-92. [DOI:10.1007/s00259-013-2664-8]
13. Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O'Malley JP. 18F-FDG PET and PET/CT patient preparation: a review of the literature. Journal of nuclear medicine technology. 2014;42(1):5-13. [DOI:10.2967/jnmt.113.132621]
14. Kleinberg L, Brock M, Gibson M. Management of locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: finally a consensus. Current treatment options in oncology. 2015;16:1-16. [DOI:10.1007/s11864-015-0352-6]
15. Yorozu A, Dokiya T. Brachytherapy for esophageal cancer: optimum dose and indications in the modern era. Brachytherapy: Techniques and Evidences. 2019:283-300. [DOI:10.1007/978-981-13-0490-3_21]
16. Scarpa M, Valente S, Alfieri R, Cagol M, Diamantis G, Ancona E, et al. Systematic review of health-related quality of life after esophagectomy for esophageal cancer. World journal of gastroenterology: WJG. 2011;17(42):4660. [DOI:10.3748/wjg.v17.i42.4660]
17. Folkert MR, Gil'ad NC, Wu AJ, Gerdes H, Schattner MA, Markowitz AJ, et al. Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. Brachytherapy. 2013;12(5):463-70. [DOI:10.1016/j.brachy.2012.12.001]
18. Okamoto H, Taniyama Y, Sato C, Fukutomi T, Ozawa Y, Ando R, et al. Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome. Asian Pacific Journal of Cancer Prevention. 2022;23(2):495-9. [DOI:10.31557/APJCP.2022.23.2.495]
19. Nishimura Y, Okuno Y, Ono K, Mitsumori M, Nagata Y, Hiraoka M. External beam radiation therapy with or without high‐dose‐rate intraluminal brachytherapy for patients with superficial esophageal carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1999 Jul 15;86(2):220-8. https://doi.org/10.1002/(SICI)1097-0142(19990715)86:2<220::AID-CNCR5>3.0.CO;2-O [DOI:10.1002/(SICI)1097-0142(19990715)86:23.0.CO;2-O]
20. Gaspar LE, Nag S, Herskovic A, Mantravadi R, Speiser B. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. International journal of radiation oncology, biology, physics. 1997;38(1):127-32. [DOI:10.1016/S0360-3016(97)00231-9]
21. Sharan K, Fernandes DJ, Prakash Saxena PU, Banerjee S, Sathian B. Treatment outcomes after intraluminal brachytherapy following definitive chemoradiotherapy in patients with esophageal cancer. J Cancer Res Ther. 2014;10(2):337-41. [DOI:10.4103/0973-1482.136623]
22. Mangesius J, Hörmandinger K, Jäger R, Skvortsov S, Plankensteiner M, Maffei M, Seppi T, Dejaco D, Santer M, Sarcletti M, Ganswindt U. Chemoradiotherapy Combined with Brachytherapy for the Definitive Treatment of Esophageal Carcinoma. Cancers. 2023 Jul 12;15(14):3594. [DOI:10.3390/cancers15143594]
23. Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World journal of gastrointestinal oncology. 2014;6(8):263. [DOI:10.4251/wjgo.v6.i8.263]
24. Murakami Y, Nagata Y, Nishibuchi I, Kimura T, Kenjo M, Kaneyasu Y, Okabe T, Hashimoto Y, Akagi Y. Long-term outcomes of intraluminal brachytherapy in combination with external beam radiotherapy for superficial esophageal cancer. International journal of clinical oncology. 2012 Jun;17:263-71. [DOI:10.1007/s10147-011-0285-4]
25. Ye M, Han D, Mao Z, Cheng G. A prospective study of radical external beam radiotherapy versus external beam radiotherapy combined with intraluminal brachytherapy for primary esophageal cancer. Brachytherapy. 2022 Sep 1;21(5):703-11. [DOI:10.1016/j.brachy.2022.05.008]
26. Gaspar LE, Winter K, Kocha WI, Pinover WH, Graham M, Gunderson L. Swallowing function and weight change observed in a phase I/II study of external-beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 9207). Cancer Journal (Sudbury, Mass). 2001;7(5):388-94.
27. Fuccio L, Mandolesi D, Farioli A, Hassan C, Frazzoni L, Guido A, et al. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies. Radiotherapy and Oncology. 2017;122(3):332-9. [DOI:10.1016/j.radonc.2016.12.034]
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb